Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 74,681 | 58,839 | 44,575 | 39,843 | 10,178 |
| Cost of Goods | 70,953 | 45,238 | 42,587 | 48,275 | N/A |
| Gross Profit | 3,728 | 13,601 | 1,988 | -8,432 | 10,178 |
| Operating Expenses | 652,813 | 492,843 | 352,635 | 237,570 | 192,953 |
| Operating Income | -648,132 | -479,004 | -350,060 | -245,727 | -182,775 |
| Other Income | 3,237 | 14,216 | 17,932 | 6,251 | -3,704 |
| Pre-tax Income | -644,895 | -464,788 | -332,128 | -239,476 | -186,479 |
| Income Tax | -136 | -1,127 | -4,062 | N/A | N/A |
| Net Income Continuous | -644,759 | -463,661 | -328,066 | -239,476 | -186,479 |
| Net Income | $-644,759 | $-463,661 | $-328,066 | $-239,476 | $-186,479 |
| EPS Basic Total Ops | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
| EPS Basic Continuous Ops | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
| EPS Diluted Total Ops | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
| EPS Diluted Continuous Ops | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
| EPS Diluted Before Non-Recurring Items | -1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
| EBITDA(a) | $-564,431 | $-442,510 | $-325,658 | $-233,971 | $-174,370 |